Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapySecond-generation inhibitors of Bruton tyrosine kinaseChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyManagement of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Pseudokinases: update on their functions and evaluation as new drug targets.Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaEditing of mouse and human immunoglobulin genes by CRISPR-Cas9 system.Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with IbrutinibHM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritisA rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapyHow to unleash mitochondrial apoptotic blockades to kill cancers?New Pharmacotherapies in Chronic Lymphocytic Leukemia.Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.An update for Richter syndrome - new directions and developments.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Breakthrough therapies in B-cell non-Hodgkin lymphoma.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.Targeting of B-cell receptor signalling in B-cell malignancies.The molecular pathogenesis of chronic lymphocytic leukaemia.Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.From identification of the BTK kinase to effective management of leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.
P2860
Q26738946-A56EBE38-569F-4E7F-BB98-7A8BB9F8186BQ26764833-F577E19C-35E5-487F-A05F-925AECE3A848Q26765624-C2280924-AF44-4D91-AC84-A9295A540413Q28066316-0311AE91-BADC-494F-B81C-832D8B742862Q28070090-C3306798-18B7-4644-A146-8D86C57C844EQ28076118-9EFE814F-0D6D-4235-A911-C811A6BE707DQ28080304-67C006F7-E7E5-4169-B0B7-E794A7F29288Q30243914-B13D77BB-3B7A-4D91-B322-AD0D759796F7Q30243968-7302B972-57F2-41E9-9A3A-F262E2D93128Q30252869-DAC4FB6B-49E8-4BC6-8E51-AA8D2E5146F4Q30397636-B396A467-F3AF-4272-8F99-4B8A8778DFD3Q31097476-E0B1C08B-746D-45F4-A318-706E6099EDC2Q33774517-B8971998-8EA6-434A-A42A-BDF977962C92Q34534572-D19BAE67-5FDD-4A86-824B-5E0603592912Q36675192-DBE2CB37-C701-4A3A-A5A9-533EFB48CE10Q36759082-6E9CE7D9-46BA-4667-BF3C-63242FB8D6EBQ36810546-6A416D58-2A80-43DB-BAC4-048127C3B508Q37119773-8CBCFFB2-07D8-4F40-8EA8-25234FF176F5Q37168430-BC97D20C-5EDA-462E-BF0B-833BC7BCC04AQ37587294-98E2091C-9F34-4307-8FE6-1709BBB793D3Q37605306-20BBAAA5-EDD5-4105-AED2-A0D36EF4DB07Q38616907-802EC8B5-F6CD-42D9-94B8-3AAC22247AC5Q38646074-FE8108D8-E383-47BE-B4BD-0DE0E619E21DQ38646974-2F3200D0-C111-4BAC-A3EF-167BA8D9B8E5Q38654101-0FAC410E-EB3E-426D-9399-86B2D632C993Q38665207-44B2C8B4-623E-411F-AEF3-168AD213DC46Q38685006-6B4BABA3-0443-4A2B-8169-1F71D649E5DEQ38691261-6AD38DC5-696D-4048-93A5-D04E2E9678B9Q38691282-6EA47DAC-990E-400B-8C29-C1E501D3C3B2Q38708600-E22EC820-5AC2-422E-8F04-8D1C36CD5A83Q38719429-5D15D172-ECA3-41C8-A0AC-432A550B528EQ38738661-41375730-BD01-497B-A193-51041FB98C5DQ38744922-0CC411F0-9152-4B42-A623-0AD77633619DQ38748645-8353C2F4-4EDA-4FF4-B3FD-368EE7C2B5ADQ38765458-69DC3D5E-1CA6-4C22-A7A2-80DD4B3DF8DAQ38766548-5461F12C-EF9B-49A8-AAF2-9B14FBFDCB65Q38782141-1F134420-2F9E-4B89-BF64-24AA9A3A8295Q38817591-0E0C74ED-6FE8-4EDD-99FC-A51D17CB88C0Q38818283-DD591F13-12B1-47B0-822E-718F6F54181AQ38819164-C8DF1AF4-D199-4F39-8470-932C949F284E
P2860
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en-gb
type
label
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en-gb
prefLabel
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en-gb
P2093
P2860
P50
P356
P1476
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
@en
P2093
Ahmed Hamdy
Allard Kaptein
Amy J Johnson
Anna Schuh
Brian J Lannutti
Dave Johnson
Farrukh T Awan
Jacqueline C Barrientos
Jane Huang
Jeffrey A Jones
P2860
P304
P356
10.1056/NEJMOA1509981
P407
P50
P577
2015-12-07T00:00:00Z